OCI NV (OCI.AS)

NL0010558797 - Common Stock

10.905  +0.01 (+0.09%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OCI. OCI was compared to 65 industry peers in the Chemicals industry. OCI has a bad profitability rating. Also its financial health evaluation is rather negative. OCI does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

OCI had negative earnings in the past year.
In the past year OCI had a positive cash flow from operations.
In multiple years OCI reported negative net income over the last 5 years.
In the past 5 years OCI always reported a positive cash flow from operatings.

1.2 Ratios

The Return On Assets of OCI (-5.57%) is worse than 74.60% of its industry peers.
The Return On Equity of OCI (-54.32%) is worse than 90.48% of its industry peers.
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROIC N/A
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 2.10%, OCI is doing worse than 87.30% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for OCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

OCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCI has about the same amount of shares outstanding.
Compared to 5 years ago, OCI has more shares outstanding
OCI has a better debt/assets ratio than last year.

2.2 Solvency

OCI has an Altman-Z score of 0.20. This is a bad value and indicates that OCI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of OCI (0.20) is worse than 84.13% of its industry peers.
OCI has a debt to FCF ratio of 44.52. This is a negative value and a sign of low solvency as OCI would need 44.52 years to pay back of all of its debts.
OCI has a Debt to FCF ratio of 44.52. This is in the lower half of the industry: OCI underperforms 61.90% of its industry peers.
OCI has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.03, OCI is not doing good in the industry: 95.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Altman-Z 0.2
ROIC/WACCN/A
WACC5.46%

2.3 Liquidity

OCI has a Current Ratio of 1.39. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
OCI's Current ratio of 1.39 is on the low side compared to the rest of the industry. OCI is outperformed by 76.19% of its industry peers.
OCI has a Quick Ratio of 1.37. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, OCI is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.37

1

3. Growth

3.1 Past

OCI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -123.19%.
Looking at the last year, OCI shows a very negative growth in Revenue. The Revenue has decreased by -63.19% in the last year.
Measured over the past years, OCI shows a decrease in Revenue. The Revenue has been decreasing by -9.61% on average per year.
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%

3.2 Future

OCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.31% yearly.
The Revenue is expected to decrease by -15.65% on average over the next years. This is quite bad
EPS Next Y98.61%
EPS Next 2Y68.27%
EPS Next 3Y47.19%
EPS Next 5Y26.31%
Revenue Next Year-49.31%
Revenue Next 2Y-30.18%
Revenue Next 3Y-20.01%
Revenue Next 5Y-15.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCI. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 17.64, which indicates a rather expensive current valuation of OCI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of OCI is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, OCI is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.64

4.2 Price Multiples

OCI's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 44.45
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OCI's earnings are expected to grow with 47.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.27%
EPS Next 3Y47.19%

0

5. Dividend

5.1 Amount

OCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OCI NV

AMS:OCI (12/24/2024, 7:00:00 PM)

10.905

+0.01 (+0.09%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-12 2024-11-12
Earnings (Next)02-12 2025-02-12/amc
Inst Owners30.9%
Inst Owner ChangeN/A
Ins Owners8.71%
Ins Owner ChangeN/A
Market Cap2.30B
Analysts77.14
Price Target16.08 (47.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP-34.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)486.8%
Min EPS beat(2)232.01%
Max EPS beat(2)741.58%
EPS beat(4)2
Avg EPS beat(4)85.49%
Min EPS beat(4)-492.57%
Max EPS beat(4)741.58%
EPS beat(8)3
Avg EPS beat(8)31.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)37.56%
Min Revenue beat(2)20.15%
Max Revenue beat(2)54.98%
Revenue beat(4)2
Avg Revenue beat(4)8.41%
Min Revenue beat(4)-23.05%
Max Revenue beat(4)54.98%
Revenue beat(8)5
Avg Revenue beat(8)21.58%
Revenue beat(12)9
Avg Revenue beat(12)32.19%
Revenue beat(16)12
Avg Revenue beat(16)36.43%
PT rev (1m)-46.75%
PT rev (3m)-50.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-112.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.64
P/S 0.59
P/FCF 44.45
P/OCF 4.33
P/B 2.6
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)0.62
Fwd EY5.67%
FCF(TTM)0.25
FCFY2.25%
OCF(TTM)2.52
OCFY23.08%
SpS18.39
BVpS4.19
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 2.1%
FCFM 1.33%
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Debt/EBITDA N/A
Cap/Depr -4159.17%
Cap/Sales 12.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.37
Altman-Z 0.2
F-Score4
WACC5.46%
ROIC/WACCN/A
Cap/Depr(3y)123.26%
Cap/Depr(5y)93.86%
Cap/Sales(3y)13.94%
Cap/Sales(5y)11.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
EPS Next Y98.61%
EPS Next 2Y68.27%
EPS Next 3Y47.19%
EPS Next 5Y26.31%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%
Revenue Next Year-49.31%
Revenue Next 2Y-30.18%
Revenue Next 3Y-20.01%
Revenue Next 5Y-15.65%
EBIT growth 1Y-116.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.37%
EBIT Next 3Y6.31%
EBIT Next 5Y-0.48%
FCF growth 1Y-98.26%
FCF growth 3Y-23.28%
FCF growth 5Y-15.81%
OCF growth 1Y-83.68%
OCF growth 3Y4.02%
OCF growth 5Y0.7%